In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Motif Bio plc (MTFB), with a price target of $5. The company’s shares closed on Friday at $0.63, close to its 52-week low of $0.60.
Byrnes noted:
“We anticipate the Type B meeting to occur within 60 days, with a potential update from the Company in the mid-October timeframe.”
According to TipRanks.com, Byrnes has 0 stars on 0-5 star ranking scale with an average return of -10.4% and a 23.7% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals Inc, Opiant Pharmaceuticals Inc, and Adamas Pharmaceuticals.
Currently, the analyst consensus on Motif Bio plc is a Moderate Buy with an average price target of $5.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.45 and a one-year low of $0.60. Currently, Motif Bio plc has an average volume of 117.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Motif Bio Plc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.
